ESH AL 2018 | FLT3 inhibitors in the treatment of AML
Farhad Ravandi
Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, describes which FLT3 inhibitors his group uses to treat different subsets of patients with acute myeloid leukemia (AML ). This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
Related videos
2:03 ESH AL highlights: management of T-cell malignancies
John DiPersio
3:57 Targeting T-cell malignancies with CRISPR/Cas9 gene edited universal CAR-T
John DiPersio
2:10 Advances in the field of HSCT
Sergio Giralt
8:34 Clinical practice recommendation on HSCT for AML with FLT3-internal tandem duplication
Zinaida Perić
6:59 Reduced-intensity conditioning regimens in ALL patients undergoing allo-HSCT
Zinaida Perić
